The aim of our article is to provide a concise review for clinicians entailing the main studies
that evaluated the efficacy and safety of target-specific oral anticoagulants (TSOAs) for …

Background Stroke is the most serious clinical consequence of atrial fibrillation, which is the
most common cardiac arrhythmia. Non-vitamin K antagonist oral anticoagulants (NOACs) …

Atrial fibrillation (AF) is the most prevalent arrhythmia and is associated with an increased
risk of ischemic stroke (IS) and systemic embolism (SE). Stroke prevention is a key element …

Atrial fibrillation (AF) confers a significant risk of stroke or systemic thromboembolism. Oral
anticoagulation is the most effective therapy for AF-related stroke prevention. A decision to …

Dabigatran, a direct thrombin inhibitor and 2 factor Xa inhibitors, rivaroxaban and apixaban,
are target‑‑specific oral anticoagulants (TSOACs) approved for prevention of stroke or …

Background and Purpose—Evidence from the real-world setting complements evidence
coming from randomized controlled trials. We aimed to summarize all available evidence …

Atrial fibrillation (AF) is the most common cardiac arrhythmia worldwide. Strokes that occur
as a complication of AF are usually more severe and associated with a higher disability or …

The novel oral anticoagulants (NOACs) apixaban, dabigatran, and rivaroxaban have been
recently indicated for stroke prevention in patients with atrial fibrillation (AF). Due to a lack of …

Background: To review data from the pivotal phase III trials evaluating the efficacy and safety
of direct oral anticoagulants (DOACs) versus warfarin for stroke prevention in patients with …

Purpose: To systematically review available evidence of indirect comparisons from RCTs
and direct comparisons from observational studies regarding the comparative effectiveness …